LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Impact of natural disasters and pandemics on blood supply

    Flavia Torres Vasconcelos / Helen M. Faddy / Katharina M.D. Merollini / Robert L.P. Flower / Melinda M. Dean / Elvina Viennet

    Health Sciences Review, Vol 7, Iss , Pp 100087- (2023)

    A systematic review

    2023  

    Abstract: Background: Natural disasters and pandemics can be highly challenging to blood supply chains. This review aimed to assess the impacts of pandemics and natural disasters on blood donation globally, appraise any similarities and differences, and provide an ...

    Abstract Background: Natural disasters and pandemics can be highly challenging to blood supply chains. This review aimed to assess the impacts of pandemics and natural disasters on blood donation globally, appraise any similarities and differences, and provide an overview of the mitigation strategies and optimizations applied as well as risks modelling undertaken. Methods: Full text, peer-reviewed articles that studied the impact of any pandemic and natural disaster on blood donation, blood supply management, and modelling searchable in PubMed, Scopus, Web of Science, and Cochrane Library between Jan 1980 and Jan 2023, inclusive were included. We performed quality assessments and summarised potential lessons learned. Results: Overall, 98 studies were identified and assessed in this review, of which 58 were related to pandemics and 17 related to natural disasters. 97% of the studies on pandemics and blood donation were on COVID-19, while 88% of studies on natural disasters were on earthquakes. We confirmed that during the COVID-19 pandemic, blood donation numbers decreased compared to the pre-pandemic period, while just after an earthquake, blood donation numbers tended to increase, which in both cases put the blood supply chain under pressure (creating shortage or wastage). The increase of first-time donors was higher after a sudden destructive earthquake than after the COVID-19 pandemic. Public awareness campaigns, donors transportation, home visits, measures to minimize wastage of blood components, activation of contingency plans, and altering donor eligibility criteria were implemented to help the blood supply chain to respond to the demand and reduce wastage. However, no pandemic plans, per se were identified highlighting the lack of an emergency plan in collaboration with health authorities. Several optimization models were developed to help the blood supply chain reduce costs and identify faster transportation in times of earthquake, however, optimization models targeting a pandemic were lacking, as were risk ...
    Keywords Blood donation ; Pandemic ; Natural disaster ; Blood supply ; Mitigation strategies ; Modelling ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2023-06-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Cancer Survivors’ Long-Term Health Service Costs in Queensland, Australia

    Katharina M. D. Merollini / Louisa G. Gordon / Yiu M. Ho / Joanne F. Aitken / Michael G. Kimlin

    International Journal of Environmental Research and Public Health, Vol 19, Iss 9473, p

    Results of a Population-Level Data Linkage Study (Cos-Q)

    2022  Volume 9473

    Abstract: Worldwide, the number of cancer survivors is rapidly increasing. The aim of this study was to quantify long-term health service costs of cancer survivorship on a population level. The study cohort comprised residents of Queensland, Australia, diagnosed ... ...

    Abstract Worldwide, the number of cancer survivors is rapidly increasing. The aim of this study was to quantify long-term health service costs of cancer survivorship on a population level. The study cohort comprised residents of Queensland, Australia, diagnosed with a first primary malignancy between 1997 and 2015. Administrative databases were linked with cancer registry records to capture all health service utilization. Health service costs between 2013–2016 were analyzed using a bottom-up costing approach. The cumulative mean annual healthcare expenditure (2013–2016) for the cohort of N = 230,380 individuals was AU$3.66 billion. The highest costs were incurred by patients with a history of prostate (AU$538 m), breast (AU$496 m) or colorectal (AU$476 m) cancers. Costs by time since diagnosis were typically highest in the first year after diagnosis and decreased over time. Overall mean annual healthcare costs per person (2013–2016) were AU$15,889 (SD: AU$25,065) and highest costs per individual were for myeloma (AU$45,951), brain (AU$30,264) or liver cancer (AU$29,619) patients. Our results inform policy makers in Australia of the long-term health service costs of cancer survivors, provide data for economic evaluations and reinforce the benefits of investing in cancer prevention.
    Keywords cancer survivors ; health service use ; costs and cost analysis ; health economics ; Medicine ; R
    Subject code 360
    Language English
    Publishing date 2022-08-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Lifetime Costs of Surviving Cancer—A Queensland Study (COS-Q)

    Katharina M. D. Merollini / Louisa G. Gordon / Joanne F. Aitken / Michael G. Kimlin

    International Journal of Environmental Research and Public Health, Vol 17, Iss 2831, p

    Protocol of a Large Healthcare Data Linkage Study

    2020  Volume 2831

    Abstract: Australia-wide, there are currently more than one million cancer survivors. There are over 32 million world-wide. A trend of increasing cancer incidence, medical innovations and extended survival places growing pressure on healthcare systems to manage ... ...

    Abstract Australia-wide, there are currently more than one million cancer survivors. There are over 32 million world-wide. A trend of increasing cancer incidence, medical innovations and extended survival places growing pressure on healthcare systems to manage the ongoing and late effects of cancer treatment. There are no published studies of the long-term health service use and cost of cancer survivorship on a population basis in Australia. All residents of the state of Queensland, Australia, diagnosed with a first primary malignancy from 1997–2015 formed the cohort of interest. State and national healthcare databases are linked with cancer registry records to capture all health service utilization and healthcare costs for 20 years (or death, if this occurs first), starting from the date of cancer diagnosis, including hospital admissions, emergency presentations, healthcare costing data, Medicare services and pharmaceuticals. Data analyses include regression and economic modeling. We capture the whole journey of health service contact and estimate long-term costs of all cancer patients diagnosed and treated in Queensland by linking routinely collected state and national healthcare data. Our results may improve the understanding of lifetime health effects faced by cancer survivors and estimate related healthcare costs. Research outcomes may inform policy and facilitate future planning for the allocation of healthcare resources according to the burden of disease.
    Keywords cancer survivors ; health service use ; costs and cost analysis ; long-term outcomes ; economic models ; health economics ; Medicine ; R
    Subject code 360
    Language English
    Publishing date 2020-04-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Estimated Healthcare Costs of Melanoma and Keratinocyte Skin Cancers in Australia and Aotearoa New Zealand in 2021

    Louisa G. Gordon / William Leung / Richard Johns / Bronwen McNoe / Daniel Lindsay / Katharina M. D. Merollini / Thomas M. Elliott / Rachel E. Neale / Catherine M. Olsen / Nirmala Pandeya / David C. Whiteman

    International Journal of Environmental Research and Public Health, Vol 19, Iss 3178, p

    2022  Volume 3178

    Abstract: Australia and Aotearoa New Zealand have the highest incidence of melanoma and KC in the world. We undertook a cost-of-illness analysis using Markov decision–analytic models separately for melanoma and keratinocyte skin cancer (KC) for each country. Using ...

    Abstract Australia and Aotearoa New Zealand have the highest incidence of melanoma and KC in the world. We undertook a cost-of-illness analysis using Markov decision–analytic models separately for melanoma and keratinocyte skin cancer (KC) for each country. Using clinical pathways, the probabilities and unit costs of each health service and medicine for skin cancer management were applied. We estimated mean costs and 95% uncertainty intervals (95% UI) using Monte Carlo simulation. In Australia, the mean first-year costs of melanoma per patient ranged from AU$644 (95%UI: $642, $647) for melanoma in situ to AU$100,725 (95%UI: $84,288, $119,070) for unresectable stage III/IV disease. Australian-wide direct costs to the Government for newly diagnosed patients with melanoma were AU$397.9 m and AU$426.2 m for KCs, a total of AU$824.0 m. The mean costs per patient for melanoma ranged from NZ$1450 (95%UI: $1445, $1456) for melanoma in situ to NZ$77,828 (95%UI $62,525, $94,718) for unresectable stage III/IV disease. The estimated total cost to New Zealand in 2021 for new patients with melanoma was NZ$51.2 m, and for KCs, was NZ$129.4 m, with a total combined cost of NZ$180.5 m. These up-to-date national healthcare costs of melanoma and KC in Australia and New Zealand accentuate the savings potential of successful prevention strategies for skin cancer.
    Keywords melanoma ; keratinocyte cancer ; basal cell carcinoma ; squamous cell carcinoma ; cost-of-illness ; Markov model ; Medicine ; R
    Subject code 360
    Language English
    Publishing date 2022-03-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top